The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin

被引:32
作者
Dropinski, Jerzy [1 ]
Jakiela, Bogdan [1 ]
Sanak, Marek [1 ]
Wegrzyn, Woiciech [1 ]
Biernat, Marta [1 ]
Dziedzina, Sylvvia [1 ]
Plutecka, Hanna [1 ]
Szczeklik, Andrew [1 ]
机构
[1] Jagiellonian Univ, Dept Med, PL-31066 Krakow, Poland
关键词
aggregation; aspirin; clopidogrel; flow cytometry; platelets;
D O I
10.1160/TH06-12-0722
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We searched for additional anti-platelet effects of clopidogrel in coronary artery disease (CAD) patients treated with aspirin. Response to clopidogrel was also stratified according to aspirin resistance. Out of 76 screened aspirin-treated CAD male patients, five were aspirin-resistant based on arachidonic acid (AA) and ADP aggregometry. These five patients and 15 aspirin-sensitive patients entered the proper study. Platelet function was assessed at baseline and after one week of additional clopidogrel treatment using aggregometry, flow cytometry (ADRTRAP-6) and platelet reactivity index (PRI) based on VASP (vasodilator-stimulated phosphoprotein) expression. We evaluated the same markers in 15 healthy men after aspirin treatment. In healthy subjects aspirin did not affect resting or ADP-induced activated GPIIb/IIIa and P-selectin expression. The P-selectin expression on ADP-activated platelets was increased (p < 0.01) in aspirin treated ASA-resistant CAD patients as compared to ASA-sensitive group or aspirin-treated healthy subjects. Clopidogrel significantly decreased ADP and AA-induced platelet aggregation and overcame aspirin resistance in four of five patients. Expression of ADP-induced activation markers was significantly lowered after clopidogrel in all patients. Out of 20 patients,five did not respond to clopidogrel (< 10% inhibition of ADP aggregation), and this group showed no change in expression of ADP-induced activation markers after clopidogrel. Clopidogrel treatment significantly reduced PRI only in the clopidogrel-sensitive group. In conclusion, the addition of clopidogrel to aspirin provides greater inhibition of platelets and can overcome aspirin resistance. Flow cytometric analysis of platelets is useful for monitoring of clopidogrel therapy.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 41 条
[1]   Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases [J].
Aleil, B ;
Ravanat, C ;
Cazenave, JP ;
Rochoux, G ;
Heitz, A ;
Gachet, C .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :85-92
[2]   Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717
[3]   Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans [J].
Cadroy, Y ;
Bossavy, JP ;
Thalamas, C ;
Sagnard, L ;
Sakariassen, K ;
Boneu, B .
CIRCULATION, 2000, 101 (24) :2823-2828
[4]  
CATTANEO M, 2004, ARTERIOSCLER THROMB, V109, P3171
[5]   Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial [J].
Chen, ZM ;
Jiang, LX ;
Chen, YP ;
Xie, JX ;
Pan, HC ;
Peto, R ;
Collins, R ;
Liu, LS ;
Chen, ZM ;
Liu, LS ;
Collins, R ;
Jiang, LX ;
Chen, YP ;
Xie, JX ;
Pan, HC ;
Peto, R ;
Cai, NS ;
Chen, YZ ;
Cui, JJ ;
Dai, GZ ;
Feng, JZ ;
Fu, SY ;
Gent, M ;
Gong, LS ;
Hu, DY ;
Huang, DJ ;
Huang, J ;
Huang, TG ;
Huang, ZW ;
Hui, RT ;
Jiang, BQ ;
Li, DY ;
Li, SM ;
Li, TD ;
Li, YQ ;
Li, ZQ ;
Liu, YH ;
Meng, QY ;
Qian, TJ ;
San, J ;
Tao, SQ ;
Wang, DW ;
Wang, LH ;
Wang, W ;
Wu, HA ;
Xi, WH ;
Xu, CB ;
Yang, DC ;
Yang, XF ;
Yin, JQ .
LANCET, 2005, 366 (9497) :1607-1621
[6]   Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial [J].
Eikelboom, JW ;
Hankey, GJ ;
Thom, J ;
Claxton, A ;
Yi, Q ;
Gilmore, G ;
Staton, J ;
Barden, A ;
Norman, PE .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (12) :2649-2655
[7]   Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway - A 700-patient study of aspirin resistance [J].
Frelinger, Andrew L., III ;
Furman, Mark I. ;
Linden, Matthew D. ;
Li, Youfu ;
Fox, Marsha L. ;
Barnard, Marc R. ;
Michelson, Alan D. .
CIRCULATION, 2006, 113 (25) :2888-2896
[8]  
FUSTER V, 1992, NEW ENGL J MED, V326, P310
[9]   Specific impairment of human platelet P2YAC ADP receptor-mediated signalling by the antiplatelet drug clopidogrel [J].
Geiger, J ;
Brich, J ;
Hönig-Liedl, P ;
Eigenthaler, M ;
Schanzenbächer, P ;
Herbert, JM ;
Walter, U .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (08) :2007-2011
[10]   Variable extent of clopidogrel responsiveness in patients after coronary stenting [J].
Grossmann, R ;
Sokolova, O ;
Schnurr, A ;
Bonz, A ;
Porsche, C ;
Obergfell, A ;
Lengenfelder, B ;
Walter, U ;
Eigenthaler, M .
THROMBOSIS AND HAEMOSTASIS, 2004, 92 (06) :1201-1206